Vicarious Surgical president shifts to board role

WALTHAM, Mass. - Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS), currently trading at $8.06 per share, announced today that its President, Randy Clark, will transition to a new role as a member of the company’s Board of Directors, effective April 25, 2025, subject to standard conflict checks. According to InvestingPro data, the company maintains a strong liquidity position with more cash than debt on its balance sheet, though it faces challenges with rapid cash burn.

During his tenure as President, Clark has been instrumental in overseeing product development, operations, and various other critical business functions. He has played a key role in the strategic expansion of the company’s manufacturing capabilities, including forming essential partnerships and fortifying the supply chain. His efforts in personnel realignment and the streamlining of business processes have been credited with preparing Vicarious Surgical for its next growth phase, though the company’s financial health score remains weak at 1.56 according to InvestingPro metrics.

Adam Sachs, Co-founder and CEO of Vicarious Surgical, expressed gratitude for Clark’s dedication and leadership, stating that the company has built a strong foundation for future growth under his presidency. Sachs looks forward to Clark’s continued contribution to the company in his new capacity on the board.

Clark reflected on his time as President with appreciation for the team and board, emphasizing the company’s readiness to execute its strategy and reach its milestones. He expressed comfort in taking on the new role, knowing he will remain involved with Vicarious Surgical’s journey.

Vicarious Surgical, founded in 2014, is known for its novel approach to robotic surgery, aiming to enhance the efficiency of surgical procedures, improve patient outcomes, and reduce healthcare costs. The company’s technology features proprietary human-like surgical robots that enable minimally invasive surgery by virtually transporting surgeons inside the patient. While the stock has seen significant volatility with a -19.73% return over the past week, it has shown strength over a longer term with a +41.58% return over six months. Detailed analysis and additional insights are available in the comprehensive Pro Research Report on InvestingPro.

The company, headquartered in Waltham, Massachusetts, is backed by notable figures and firms in technology, including Bill Gates and Vinod Khosla’s Khosla Ventures.

This announcement is based on a press release statement from Vicarious Surgical Inc. and contains forward-looking statements that involve risks and uncertainties. The actual results may differ from the company’s projections. Factors that could cause such differences include market conditions, regulatory approvals, product development and commercialization, financing capabilities, and competition, among others.

In other recent news, Vicarious Surgical Inc. reported a fourth-quarter adjusted earnings per share (EPS) of -$2.43, which was better than the expected -$2.69 by analysts. The company disclosed zero revenue for the quarter, and its operating expenses totaled $15 million, with a year-end cash balance of approximately $49 million. Looking ahead, Vicarious Surgical projects a cash burn of about $50 million for 2025, similar to the previous year. The company has successfully integrated its Version 1.0 surgical robotic system, marking a significant development milestone despite facing supply chain issues that delayed its clinical trials to late 2025. Piper Sandler adjusted its price target for Vicarious Surgical to $8.50 from $10.50, maintaining a Neutral rating. BTIG analysts also retained a Neutral rating, noting the company’s need to address financial challenges in the current economic climate. Vicarious Surgical’s management emphasized the importance of securing non-dilutive financing or reducing cash burn to sustain operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.